Remove Compounding Remove Pharmaceutical Companies Remove Presentation
article thumbnail

AI and automation to drive “substantial progress” in pharmaceutical analytical testing

European Pharmaceutical Review

The market is furthermore expected to see a compound annual growth rate (CAGR) of 7.3 An increasing trend of outsourcing boosts growth of the market as pharmaceutical companies are utilising advanced testing capabilities and optimising their drug development processes. billion by 2032. percent between 2024 and 2032.

article thumbnail

Mapping the crisis: How data can help fix America’s growing pharmacy deserts

pharmaphorum

Skip to main content Thursday 12 June 2025 BlueSky linkedin youtube rss User account menu Subscribe Channels Channels Digital Market Access Oncology Patients R&D Sales & Marketing Spotlight on Content type Content type Digital -News -Views & Analysis -Deep Dive -Webinars -Podcasts -Video -White Papers -Event Market Access -News -Views & (..)

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Pharmacists Reimagine Myeloma Care With Insights from ASCO

Pharmacy Times

In an interview with Pharmacy Times® , Gabe Hinojosa, PharmD, BCOP, clinical pharmacy specialist oncology/hematology at UT Southwestern, discussed the evolving treatment landscape for multiple myeloma (MM) and presented data from the 2025 American Society of Clinical Oncology Annual Meeting (ASCO).

article thumbnail

Understanding Recent Changes to 505(b)(2) Drugs and Reimbursement

Pharmacy Times

In 2022, based upon a complaint filed by a pharmaceutical company, CMS was asked to reevaluate the SSA section that establishes the J-code,” Soefje said. So, the pharmaceutical companies then pushed to get their 505(b)(2) drugs declared sole source,” Soefje said. “If This went into effect in January 2022.”

FDA
article thumbnail

Research Underscores the Critical Role of Pharmacists in Managing Stiff Person Syndrome

Pharmacy Times

4 There are different types of SPS based on clinical and physical presentation. Magnetic resonance imaging of the brain and spinal cord is also commonly performed to exclude structural or demyelinating diseases that could present similar symptoms. Treatment options often require trial, monitoring, and adjustment as needed.

article thumbnail

Senator Durbin Has Questions About FDA’s “Operational Capacity” to Oversee DTC Prescription Drug Advertising Amid Workforce Reductions – Don’t We All?

The FDA Law Blog

Commissioner Makary has taken a more subdued stance, stating in a podcast with Megyn Kelly that FDA doesnt have any plans to ban direct-to-consumer advertising, but there are some things that we can do to make sure that the information being presented is a complete picture. flip the Health & Economy piece on the NIH website.)

article thumbnail

What is the Timeline for True AI Implementation for Digital Twins?

PharmExec

When you have poor design, that in and of itself can cause poor performance with enrollment, which compounds with the issues the site may already have with enrollment. Li: We’re current working with three of the top 10 pharmaceutical companies to create better clinical trial designs, better patient recruitment, and improve site performance.